Drug intelligence / Profile preview

TLD-1

Development stage: Phase 1
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

TLD-1 is a novel PEGylated liposomal formulation of doxorubicin, an anthracycline chemotherapeutic. It was developed to improve the benefit-risk profile of conventional liposomal doxorubicin formulations, such as Caelyx/Doxil, by optimizing particle features like size, charge distribution, lipid composition, and drug release. Preclinical studies suggested that TLD-1 could potentially reduce side effects like palmar-plantar erythrodysesthesia (hand-foot syndrome) due to a shorter plasma half-life compared to Caelyx, while maintaining promising activity and good tolerability. It aims to combine the cardio-preserving properties of liposomal delivery with reduced systemic toxicity.

Other names: Targeted liposomal doxorubicin

Targets

DNATOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on TLD-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLD-1.

Explore the full profile